Start Submission Become a Reviewer

Reading: Alcohol Septal Ablation Therapy for Patients with Hypertrophic Obstructive Cardiomyopathy

Download

A- A+
Alt. Display

Review Articles

Alcohol Septal Ablation Therapy for Patients with Hypertrophic Obstructive Cardiomyopathy

Authors:

John M. Buergler ,

Jennifer Franklin,

Sherif F. Nagueh

From Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, US
X close

Abstract

Hypertrophic cardiomyopathy is a common genetic disorder that can lead to significant morbidity and mortality, particularly in patients with dynamic left-ventricular outflow tract obstruction (HOCM). Alcohol septal ablation (ASA) was recently introduced for the treatment of HOCM. It was first reported in 1995 by Dr. Ulrich Sigwart,1 and a year later Or. William H. Spencer, Ill performed the first procedure at The Methodist Hospital. Since then, several publications around the world have confirmed the procedure's efficacy and safety, and a vast majority of patients elect to undergo ASA as an alternative to surgery. This article summarizes several aspects related to ASA ranging from case selection to its comparison with surgical myectomy.
How to Cite: 1. Buergler JM, Franklin J, Nagueh SF. Alcohol Septal Ablation Therapy for Patients with Hypertrophic Obstructive Cardiomyopathy. Methodist DeBakey Cardiovascular Journal. 2005;1(3):2-3. DOI: http://doi.org/10.14797/mdcvj.58
3
Views
Published on 01 Jan 2005.
Peer Reviewed

Downloads

  • PDF (EN)